Riri Andri Muzasti
Division Of Nephrology And Hypertension, Department Of Internal Medicine Faculty Of Medicine Universitas Sumatera Utara, Jl. Dr. Mansyur, Medan, Indonesia 20155

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

MGP T-138C Polymorphism (TT Genotype) is Associated with Vascular Calcification Incidence in Indonesian Regular Hemodialysis Patients Muhammad Hanif Wibowo; Riri Andri Muzasti; Syafrizal Nasution
The Indonesian Biomedical Journal Vol 12, No 4 (2020)
Publisher : The Prodia Education and Research Institute (PERI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.18585/inabj.v12i4.1162

Abstract

BACKGROUND: Vascular calcification contributes greatly to the incidence of cardiovascular disease. Previously, vascular calcification was considered as a passive process caused by the mineral deposition from the circulation. Nowadays, researchers have found inhibitors and promoter factors from vascular calcification, one of which is the matrix gla protein (MGP). MGP levels depend on the gene that encodes them. The MGP T-138C polymorphism is one of the most common causes of vascular calcification.METHODS: This was a case-control study involving 86 chronic kidney disease (CKD) patients who underwent regular hemodialysis in Rasyida Kidney Hospital, Medan, Indonesia. Vascular calcification was determined from lateral and posteroanterior abdominal X-ray. The MGP T-138 C polymorphism was analyzed using polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP).RESULTS: The TT/TC genotype associates with the incidence of vascular calcification with OR of 3.52, 95% CI: 1.23-10.106 (p-value<0.001).CONCLUSION: There is an association between MGP T-138C polymorphism, particularly on T Allele with the incidence of vascular calcification in CKD patients undergoing regular hemodialysis.KEYWORDS: hemodialysis, T-138 C polymorphism, vascular calcification, matrix GLA protein
Immune Response and Prognosis of Chronic Kidney Disease Patients Undergoing Hemodialysis Against COVID-19: A Systematic Review Nurul Hanifa; Riri Andri Muzasti
JURNAL KEDOKTERAN DIPONEGORO (DIPONEGORO MEDICAL JOURNAL) Vol 11, No 3 (2022): JURNAL KEDOKTERAN DIPONEGORO (DIPONEGORO MEDICAL JOURNAL)
Publisher : Faculty of Medicine, Universitas Diponegoro, Semarang, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.14710/dmj.v11i3.34232

Abstract

Background: Chronic kidney disease (CKD) patients are characterized by immune response dysfunction which increased susceptibility to infections. CKD is one of the Coronavirus disease-2019 (COVID-19) comorbidity that generally has a poor clinical outcome and patients undergoing hemodialysis had a 50% hospitalization rate and 20%-30% mortality rate. Seroconversion after confirmation of COVID-19 infection is close to 100% in the dialysis population, but the durability of the immune response and the extent as a protection against infection remains unclear. This study aimed to determine the immune response and prognosis of CKD patients undergoing hemodialysis against COVID-19.Objective: To determine immune response and prognosis of CKD patients undergoing hemodialysis against COVID-19.Methods: This is a systematic review study that used literature sourced from online journal databases on Google Scholar, PubMed, Cochrane, and Clinical Key sites. Literature that has passed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) staging and the journal quality review based on the Newcastle-Ottawa Scale (NOS) assessment is then synthesized qualitatively and presented systematically.Results: Based on the data analysis, there were positive immune responses in 460 of 735 (62.6%) CKD patients undergoing hemodialysis against COVID-19 and a higher mortality rate (10.5%) than the control group (6.9%).Conclusion: The immune response and prognosis of CKD patients undergoing hemodialysis against COVID-19 were worse than the control group. Therefore, COVID-19 vaccination should be prioritized in CKD patients undergoing hemodialysis.